Citations

Clear

7 citation(s) found for "Schiavo, D".

C32-19 Caught Between Defect and Dysregulation - A Case of Immune Dysregulation in a Patient With Severe Pulmonary Nocardiosis and Chronic Granulomatous Disease
Gyimah, C, Schiavo, D, Skalski, J, Gyimah, C

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.3377 Get It

Abstract Introduction Chronic granulomatous disease (CGD) is an inherited immunodeficiency caused by NADPH oxidase defects, leading to impaired reactive oxygen species (ROS) production and defective intracellular pathogen killing. Typically diagnosed in childhood, CGD manifests as recurrent infections by catalase-positive bacteria and fungi. Immune dysregulation with hyperinflammatory responses may occur even without infection. We present a case of severe immune dysregulation in CGD with concomitant pulmonary nocardiosis. Case Summary A 37-year-old man presented with one month of progressive productive cough, fevers, malaise, vomiting, poor oral intake and high ileostomy output. He was diagnosed with X-linked CGD at age 5 which was complicated by recurrent skin infections and fulminant colitis requiring subtotal colectomy. Laboratory studies showed elevated WBC and CRP of 282.77mg/l. CT scan of chest showed widespread pulmonary nodules and dense consolidation in the left upper lobe with heterogeneous diminished enhancement suggesting necrosis (Fig 1). Cell-free pathogen DNA sequencing testing on sputum identified Nocardia cyriacigeorgica DNA. Fungal cultures on bronchoalveolar lavage grew Nocardia cyriacigeorgica. He was treated with imipinem-cilastin, sulfamethoxazole-trimethoprim, and posaconazole. His course was complicated by refractory fevers (T.max 40.5 C), septic shock, and ARDS. He had two episodes of extubation failure characterized by sudden recrudescence of fever, hemodynamic change, and worsening oxygenation. Each of these episodes occurred during steroid tapers and improved after reinitiating full stress doses. Immune dysregulation was suspected, and he was maintained on 0.8mg/kg/day of methylprednisone with plans for a prolonged taper. He gradually improved, was weaned off oxygen, and discharged home. Discussion Pulmonary nocardiosis is common in CGD, particularly without prophylaxis. Case series report that some patients fail to improve with antimicrobials alone and require adjunctive corticosteroids to control excessive inflammation, as seen in this patient. Immune dysregulation in CGD involves both defective microbial killing and excessive inflammation. Absent ROS results in persistent NF-κB and inflammasome activation, driving production of pro-inflammatory cytokines, leading to granuloma formation, autoimmunity, and IBD-like colitis. Granulomatous inflammation may cause gastrointestinal or genitourinary obstruction, and up to half of patients develop colitis. Exaggerated inflammatory responses to infection or environmental triggers can also mimic hemophagocytic lymphohistiocytosis (HLH). Concurrent susceptibility to infections and inflammation complicates diagnosis and management. Corticosteroids remain first-line for inflammatory episodes and may be combined with antibiotics, as in disseminated nocardiosis, to control hyperinflammation. However, long-term use is limited by adverse effects, and steroid-sparing agents lack proven efficacy in CGD. Hematopoietic stem cell transplantation remains the only curative option in CGD. This abstract is funded by: None
The Efficacy of Repeat Talc Pleurodesis After Initial Failure
Wireko, F.W. , Ahmed, Adil , JAIMES, GABRIEL E ORTIZ, Mullon, John J., Midthun, David E. , Anderson, D.K., SCHIAVO, DANTE N, Edell, Eric S. , ORTIZ-JAIMES, GABRIEL E, Nelson, David R. , Kern, Ryan

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4082-A4082

10.1164/ajrccm.2025.211.abstracts.a4082 Get It

Abstract Rational: Talc pleurodesis is an effective intervention for preventing recurrent pleural effusions and pneumothoraces, particularly in non-surgical candidates. Due to its efficacy and safety, it is recommended as the most effective sclerosant for pleurodesis. However, in some cases, the initial pleurodesis fails, necessitating a repeat procedure. The efficacy of repeat talc pleurodesis after an initial failure is an area that requires further exploration. This study explores the safety and efficacy of repeat talc pleurodesis among patients who did not respond to the initial intervention. Methods: This retrospective study analyzed hospitalized patients who underwent 4g talc slurry pleurodesis from 2019 to 2024, focusing on demographics, comorbidities, initial pleurodesis failure, and recurrence rates. Pleurodesis failure was identified by lung sliding, recurrent effusion, or pneumothorax during the same hospitalization. The primary outcome was recurrence post-discharge, assessed by pleural effusion or pneumothorax within 180 days post-repeat pleurodesis. Results: This study included 94 patients (52.1% male, 47.9% female) with a mean age of 67.6. Among them, 79 (84%) received a single 4g dose of talc, while 15 (16%) received multiple 4g talc doses for initial pleurodesis. Recurrence occurred in 20 (25.3%) of the single-dose group and 1 (6.7%) of the multiple-dose group within 180 days, though the difference was not statistically significant (p=0.112). Recurrence-free rates were 93.6% at 30 days, 85.1% at 90 days, and 77.7% at 180 days. Of the 20 patients with recurrence after a single 4g dose of talc, 8 (40%) underwent repeat pleurodesis, with only one recurrence requiring surgical intervention. Additionally, there was no recurrence after repeat talc pleurodesis in the one patient with recurrence after receiving multiple 4g talc doses for initial pleurodesis. No associations were found between recurrence rates and factors like gender (p=0.213) or comorbidities (emphysema, COPD, lung malignancy). Chest pain was a common complaint, but no cases of respiratory distress were reported post-pleurodesis. Conclusion: The efficacy of initial talc pleurodesis (77.7%-93.6%) in this cohort aligns with existing literature. Multiple-dose talc pleurodesis effectively prevented recurrence in 93.3% of patients, with no reported respiratory distress. Additionally, repeat talc pleurodesis was successful in 87.5% of those with recurrence after an initial single 4g dose. These findings support multiple-dose talc pleurodesis and repeat talc pleurodesis as safe and effective options for preventing recurrence post-initial failure and post-repeat talc pleurodesis, respectively. Although no significant recurrence predictors were identified, future research could focus on patient-specific factors to enhance treatment selection and optimize outcomes.
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
Tang, Jinyi , Zeng, Cong , Cox, Thomas M, Li, Chaofan , Son, Young Min , Cheon, In Su , Wu, Yue , Taylor, Justin J. , Chakaraborty, Rana, Johnson, Aaron J. , Schiavo, Dante , Utz, James P., Reisenauer, Janani , Midthun, David E. , Mullon, John J., Edell, Eric S. , Alameh, Mohamad‐Gabriel , Borish, Larry , Teague, W. Gerald , Kaplan, Mark H. , Kern, Ryan , Vassallo, Robert , Behl, Supriya, Taylor, Justin J , Chakraborty, Rana , Johnson, Aaron J. , Reisenauer, Janani S , Midthun, David E , Kaplan, Mark H , Weissman, Drew , Kern, R , Hu, Haitao , Vassallo, Robert , Liu, Shan-Lu , Sun, Jie , Tang, J , Li, Chaofan , Behl, Supriya , Chakaraborty, Rana, Liu, Shan-Lu , Sun, Jie

Mayo Clinic

Science Immunology | July 19, 2022 | Volume: 7 | Issue: 76 | Pages: No page available

10.1126/sciimmunol.add4853 | PMID 35857583 Get It

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in the respiratory tract, particularly against variants of concern (VOCs), including Omicron. We compared the SARS-CoV-2 S–specific total and neutralizing antibody responses, and B and T cell immunity, in the bronchoalveolar lavage fluid (BAL) and blood of COVID-19–vaccinated individuals and hospitalized patients. Vaccinated individuals had significantly lower levels of neutralizing antibody against D614G, Delta (B.1.617.2), and Omicron BA.1.1 in the BAL compared with COVID-19 convalescents despite robust S-specific antibody responses in the blood. Furthermore, mRNA vaccination induced circulating S-specific B and T cell immunity, but in contrast to COVID-19 convalescents, these responses were absent in the BAL of vaccinated individuals. Using a mouse immunization model, we demonstrated that systemic mRNA vaccination alone induced weak respiratory mucosal neutralizing antibody responses, especially against SARS-CoV-2 Omicron BA.1.1 in mice; however, a combination of systemic mRNA vaccination plus mucosal adenovirus-S immunization induced strong neutralizing antibody responses not only against the ancestral virus but also the Omicron BA.1.1 variant. Together, our study supports the contention that the current COVID-19 vaccines are highly effective against severe disease development, likely through recruiting circulating B and T cell responses during reinfection, but offer limited protection against breakthrough infection, especially by the Omicron sublineage. Hence, mucosal booster vaccination is needed to establish robust sterilizing immunity in the respiratory tract against SARS-CoV-2, including infection by the Omicron sublineage and future VOCs.
Successful Use of Intrapleural Triamcinolone for the Management of Recurrent Pleural Effusions from Inflammatory Pleuritis
Goel, S., Mullon, John J., Midthun, David E. , Nelson, D. K., SCHIAVO, DANTE N, Kern, R., Nelson, D., Kern, Ryan

Mayo Clinic

TP30. TP030 MORE INTERESTING CASES IN PLEURAL DISEASE | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A1963-A1963

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1963 Get It

Rituximab in Obliterative Bronchiolitis Associated with Sjorgen's Syndrome
Kubbara, Aahd , Schiavo, Dante , Weerheim, Laura E., Baqir, Misbah , Specks, Ulrich , Ryu, Jay H.

Mayo Clinic

D38. CASE REPORTS IN AUTOIMMUNE LUNG DISEASE | July 8, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6656-A6656

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6656 Get It

Risk factors for pleural effusion recurrence in patients with malignancy
Grosu, Horiana B. , Molina, Sofía, Casal, Roberto F. , Song, Juhee , Diaz‐Mendoza, Javier , Reddy, Chakravarthy, Yarmus, Lonny , Schiavo, Dante , Simoff, Michael , Johnstun, Jared, Raid, A.H. Zedan, Feller‐Kopman, David , Sahetya, Sarina K. , Foley, Finbar, Maldonado, Fabien , Noor, Laila , Miller, Russell , Mudambi, Lakshmi, Saettele, Timothy , Vial, Macarena R. , Eapen, Gerogie A., Ost, David E. , Garcia, Sofia Molina , Casal, Roberto , Yarmus, Lonny , Vial-Rodriguez, Macarena , Ost, David E , Li, Liang , Lee, Hans C. , Tian, Xin , Molina Garcia, Sofia

Mayo Clinic

Respirology | July 2, 2018 | Volume: 24 | Issue: 1 | Pages: 76-82

10.1111/resp.13362 | PMID 29966171 Get It

ABSTRACTBackground and objectiveThe main purpose of treatment in patients with malignant pleural effusion (MPE) is symptom palliation. Currently, patients undergo repeat thoracenteses prior to receiving a definitive procedure as clinicians are not aware of the risk factors associated with fluid recurrence. The primary objective of this study was to identify risk factors associated with recurrent symptomatic MPE.MethodsRetrospective multicentre cohort study of patients who underwent first thoracentesis was performed. The primary outcome was time to fluid recurrence requiring intervention in patients with evidence of metastatic disease. We used a cause‐specific hazard model to identify risk factors associated with fluid recurrence. We also developed a predictive model, utilizing Fine–Gray subdistribution hazard model, and externally validated the model.ResultsA total of 988 patients with diagnosed metastatic disease were included. Cumulative incidence of recurrence was high with 30% of patients recurring by day 15. On multivariate analysis, size of the effusion on chest X‐ray (up to the top of the cardiac silhouette (hazard ratio (HR): 1.84, 95% CI: 1.21–2.80, P = 0.004) and above the cardiac silhouette (HR: 2.22, 95% CI: 1.43–3.46, P = 0.0004)), larger amount of pleural fluid drained (HR: 1.06, 95% CI: 1.04–1.07, P < 0.0001) and higher pleural fluid LDH (HR: 1.008, 95% CI: 1.004–1.011, P < 0.0001) were associated with increased hazard of recurrence. Negative cytology (HR: 0.52, 95% CI: 0.43–0.64, P < 0.0001) was associated with decreased hazard of recurrence. The model had low prediction accuracy.ConclusionPleural effusion size, amount of pleural fluid drained, LDH and pleural fluid cytology were found to be risk factors for recurrence.
The $64,000 question
Keller, A. Scott, Schiavo, Dante , Wingo, Majken T. , Ernste, Floranne C. , Sánchez, William , Sanchez, William

Mayo Clinic

Journal of Hospital Medicine | December 24, 2014 | Volume: 10 | Issue: 2 | Pages: 112-115

10.1002/jhm.2304 | PMID 25537658 Get It